Transapical aortic valve implantation in bicuspid aortic valves: must be an absolute contraindication?

Res Cardiovasc Med. 2012 Nov;1(1):37-9. doi: 10.5812/cardiovascmed.4498. Epub 2012 Nov 1.

Abstract

Transcatheter Aortic Valve Implantation (TAVI) is a new therapeutic option for patients with severe aortic stenosis with unacceptable surgical risk for conventional aortic valve surgery. A Bicuspid Aortic Valve (BAV) is the most common congenital cardiac disorder (1% of the population) and currently is considered exclusion criteria for TAVI, because it predicts an increased risk of adverse aortic events as incomplete sealing, severe paravalvular regurgitation, or dislocation due to more frequent elliptic shape and asymmetric calcifications in BAV annulus. Only few cases have been published in recent literature, so in this case report we illustrate our experience and management of TAVI in a BAV, with excellent outcomes and no late complications at 1 year follow-up. We believe that currently the presence of a BAV might not be considered an absolute contraindication for TAVI, because although there is no sufficient data for assess the safety or efficacy of TAVI in BAV, this case report shows that it could be performed safely in selected patients with unacceptable surgical risk after an extensive preoperative evaluation, avoiding this procedure in patients with bad prognostic factors as huge and heavy calcifications, asymmetric valves, elliptic annulus or small distance from leaflets to coronary ostia. Each case must be individualized, being alert at follow-up because the risk of late complications.

Keywords: Aortic Valve; Endovascular Procedures; Heart Valve Prosthesis Implantation; TAVI.

Publication types

  • Case Reports